Skip to search formSkip to main contentSkip to account menu

GSK2879552

Known as: LSD1 Inhibitor GSK2879552 
An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzoatesCyclopropanes
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 5860: Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer
Introduction: LSD1 is a flavin adenine dinucleotide (FAD)-dependent amine oxidase that removes methyl groups from mono- or… 
2015
2015
P226 LSD1 is associated with poor prognosis in basal-like breast cancer
Review
2014
Review
2014
213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors
2014
2014
Régulation réciproque et coopération transcriptionnelle du complexe ERRalpha-LSD1
Les recepteurs nucleaires sont des facteurs de transcription qui exercent leur fonction via le controle de la transcription de… 
Review
2013
Review
2013
Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia
Lysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes… 
2012
2012
Lsd1 억제제로서의 시클로프로필아민
본 발명은 리신-특이적 데메틸라제 1(LSD1)의 활성의 조절, 특히 억제를 위한 시클로프로필아민 유도체의 용도에 관한 것이다. 적합하게는, 본 발명은 암의 치료에서의 시클로프로필아민의 용도에 관한 것이다. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)